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Aim.T oin v estigat etheeﬀectsofMnTE-2-PyPonsomemarkersofantioxidantdefencesysteminasthmamicemodel.Materialand
Methods. The animals were divided into four groups: group 1, controls; group 2, injected with ovalbumin, group 3, treated with
MnTE-2-PyP, and group 4, treated with ovalbumin and MnTE-2-PyP. The activities of superoxide dismutase, catalase, glutathione
peroxidase and nonprotein sulfhydryl groups content (NPSH) were determined in lung homogenate. Results. The activities of
superoxide dismutase and catalase in group 2 decreased signiﬁcantly as compared to control group. The decrease of the same
enzymes in group 4 was lower and signiﬁcant as compared to group 2. Changes in the glutathione peroxidase activity showed a
similar dynamics. The NPSH groups content decreased in group 2. In group 4 this decrease was relatively lower as compared to
group 2. Conclusions. The application of MnTE-2-PyP mitigated the eﬀects of oxidative stress in asthma mice model.
1.Introduction
Asthma is a major, worldwide health concern, aﬀecting
children and adults. It aﬀects 7% of the US population and
300 million worldwide [1]. Currently in the USA, some 22
million people are reported to have asthma, six million of
whom are children [2]. It is among the commonest chronic
conditions in Western countries aﬀecting 1 in 7 children
and 1 in 12 adults (equivalent to 5.1 million people in the
UK) and is responsible each year for 1500 avoidable deaths,
as well as 20 million lost working days. The annual UK
healthcare cost is estimated to be £2.5 billion [3]. Oxidative
stress is believed to play a role in the development of
number of human diseases such as cardiovascular disorders,
immunologic diseases, cancer, and asthma. A large amount
of epidemiological and clinical evidence exists to support
the relationship between increased reactive oxygen species
(ROS) and the pathogenesis of bronchial asthma [4–8].
Oxidative stress is a deleterious process that leads to lung
damageandconsequentlytovariouslungdiseases.Toprotect
against exposure to oxidants the lungs have a powerful
antioxidant system, including nonenzymatic and enzymatic
antioxidants, which may delay or prevent oxidation, but
also eliminate reactive oxygen species [5]. At high levels
of oxidative stress, however, antioxidants become depleted,
and an imbalance between oxidants and antioxidants occurs,
which causes pathological damage, or a variety of cellular
responses through formation of secondary ROS [9]. All
the major varieties of inﬂammatory lung diseases, asthma,
chronic obstructive pulmonary disease, idiopathic pul-
monary ﬁbrosis, acute respiratory distress syndrome, inter-
stitiallungdiseases,andbronchopulmonarydysplasiasharea
common feature of impaired oxidant/antioxidant ratio [10].
Therefore, the supplementation of antioxidants to boost
the endogenous antioxidants or scavenge excessive ROS
production could be utilized to prevent the inﬂammatory
responseinasthmabyrestoringoxidant-antioxidantbalance.
Current knowledge of the eﬀects of oxidative stress allow the
development of new classes of antioxidants in the treatment
of asthma and other disorders, associated with the oxidative
stress. Considerable progress has been made in the last years,
in developing mitochondria-targeted antioxidants such as
manganese porphyrins [2]. A number of water-soluble
meso-substituted manganese porphyrins with a molecular
weight above 800 quickly pass through the cell mem-








































































Figure 1: Activity of superoxide dismutase in lung homogenate.
Each point represents the mean ± SEM for six mice.
Therefore we aimed to study the eﬀect of MnTE-2-PyP
(Manganese (III) 5,10,15,20-tetrakis (N-ethylpyridinium-2-
yl) porphyrin), a manganese-meso-porphyrin also known as
AEOL-10113, on some markers of lung antioxidant defence
system in asthma mice model.
2.MaterialandMethods
2.1.Chemicals. Ovalbumin,gradeVandphosphate-buﬀered
saline (PBS) were purchased from the Sigma-Aldrich Com-
pany and Imject Alum was obtained from Pierce Chemical
Company (USA).
MnTE-2-PyP was kindly provided by Ines Batini´ c-
Haberle from the Department of Radiation Oncology, Duke
University Medical Center, Durham, NC, USA.
2.2. Animals and Experimental Protocol. The experiment was
performed in accordance with the Animal Welfare Regula-
tions and was approved by the University Ethics Committee.
The study was carried out on 24 female C57Bl/6 mice
(weight 20 ± 2.0g, 8–10 weeks old). The animals were raised
at the university vivarium at a temperature of 22 ± 2◦Ca n d
humidity of 50 ± 10%, given normal pelleted diet and water
ad libitum. The mice were divided into four groups: group
1, controls; group 2, injected with ovalbumin (OVA); group
3, treated with MnTE-2-PyP; group 4, treated with OVA and
MnTE-2-PyP.Theanimalsfromgroups1and3wereinjected
i.p. with a 100μL phosphate-buﬀed saline (PBS) + Imject
Alum (1:1) on days 0 and 14. The animals from groups
2 and 4 were injected with a 100μL ovalbumin solution,
containing 20μg OVA on the same days. On days 24, 25, and
26, mice from groups 1 and 3 were given inhalation with
PBS for 30min, and those from groups 2 and 4 were given
inhalation with a 1% ovalbumin solution (OVA dissolved
in PBS). For this purpose, a special plexiglass chamber was
used. One hour before inhalation, and 12 hours later the
animals from groups 1 and 2 were injected i.p. with 100μL
PBS,andthosefromgroups3and4receiveda100μLMnTE-
2-Pyp dissolved in PBS, containing 5mg/kg, that is, the total
daily dose was 10mg/kg. The experimental protocol was
represented in Table 1.
The solution was sterilized by ﬁltration through 0.2μm
ﬁlters.
2.3.BiochemicalAssaysintheLungHomogenate. Theanimals
were sacriﬁced on day 28 (48 hours after the last inhalation)
under thiopental anesthesia (50mg/kg). The chest was
opened and the lungs were perfused in situ via the right
heart ventricle with saline (10mL). The right lung was
ligated at the hilus, cut, and then removed from the chest
and used to prepare the lung homogenate. The tissue was
homogenized with ice-cold 0.25M sucrose in Tris HCl,
pH = 7.4, in 1:10 ratio. The homogenate was centrifuged
(9000×g, 30min), and the supernatant was stored on ice.
The superoxide dismutase (SOD) activity in U/mg lung
tissue was determined by the method of Maral et al. [13],
and catalase (CAT) activity in mcat/g tissue was assessed by
themethodofKoroljuketal.[14].Theactivityofglutathione
peroxidase (GP) in U/g lung tissue was measured by the
method of Bernchnaider, modiﬁed by Pereslegina [15]. The
non-protein sulfhydryl (NPSH) groups content in mol ×
107/g tissue was measured by the method of DeLucia et al.
[16].
2.4. Statistical Analysis. Experimental data were analyzed
using SPSS 14. When we tested for normality, two variables-
GP and CAT showed non-parametric distribution, and we
used medians, interquartile range and Mann-Whitney test
for comparison. For the rest of the variable we applied post-
hocANOVAtestanddatawerepresentedasmean ±standard
error of mean (SEM). P < 0.05 were considered statistical
signiﬁcant.
3. Results
The activities of superoxide dismutase and catalase in
group 2 (asthma-induced) decreased signiﬁcantly in the
lung homogenate up to 71% (P = 0.001) and up to 77%
(P = 0.004) respectively, as compared with the controls.
The decrease of the same parameters in group 4 was lower
(92%, P = 0.012) than that in group 2 and 91% (P =
0.006), statistically signiﬁcant compared to the group 2,
respectively (Table 2, Figures 1 and 2). Changes in the
glutathione peroxidase activity showed a similar dynamics,
such as a decrease in the OVA group (68%) and in the
values approximate to those of the controls in group 4. The
decrease was 23% less than that in group 2 but it was non
signiﬁcant. (Table 2, Figure 3). The non-protein sulfhydryl
(NPSH) groups content in the lung homogenate decreased
up to 68% in group 2 (P = 0.015), and in the group
treated with OVA and antioxidant (group 4) this decrease
was relatively lower (P = 0.045) as compared to the OVA
group (Table 2, Figure 4). The changes of the parameters
in group 3 (MnTE-2-PyP alone) did not show signiﬁcant
changes compared to controls (Figures 1–4).The Scientiﬁc World Journal 3




(on days 0 and 14)
Exposure/challenge
(on days 24, 25, and 26)
Group 1 Saline (i.p.) Saline inhalation for 30 . Saline (i.p.) 1 hour before
nebulization and 12 hours later)
Group 2 OVA OVA/alum (i.p.) OVA inhalation for 30  Saline (i.p.) 1 hour before
nebulization and 12 hours later)
Group 3 Saline (i.p.) Saline inhalation for 30 . MnTE-2-PyP (i.p.) 1 hour
before nebulization and 12 hours later)
Group 4 OVA OVA/alum (i.p.) OVA inhalation for 30 . MnTE-2-PyP (i.p.) 1 hour











































































Figure 2: Activity of catalase in lung homogenate. Each point




protein sulfhydryl groups in animals injected and inhaled
with OVA supports allegations that ovalbumin can provoke
asthma, an oxidative stress-associated disease [3, 4, 6, 17].
Some studies had revealed suppressed activity of catalase,
superoxide dismutase and glutathione peroxidase in patients
with bronchial asthma [18]. Comhair et al. also showed that
the antioxidant enzymes (SOD and CAT) are in lower levels
in asthmatic patients [19, 20]. The activity of GPx has been
found to be much lower in asthmatic children compared to
normal children [21].
MnTE-2-PyP has a beneﬁcial eﬀect on the activity of
studiedantioxidantenzymes.Metalloporphyrins,andprefer-
able water-soluble Mn complexes, remain the most stable
and the most active prospective SOD mimetics [22]. That is
way we chose and studied the eﬀects of this compound. The
activity of some manganese porphyrins approaches that of
the SOD enzymes themselves [23]. Over the year, views of
the researchers evolved from SOD mimics, to O2
−/ONOO−






































































Figure 3: Activity of glutathione peroxidase in lung homogenate.
Each point represents the median for six mice.
transcriptional activity [22]. Therefore they have at least four
antioxidant properties, such as the removal of superoxide
(O2
−•), hydrogen peroxide (H2O2), peroxinitrite (ONOO−),
and lipid peroxides [24, 25]. Given i.p. to mice at 10mg/kg
MnTE-2-PyP5+ distributed into all organs studied (liver,
kidney, spleen, lung, heart, and brain). It had high chances
to enter mitochondria. At the upper dose MnTE-2-PyP
injection was found in mitochondria at 2.9ng/mg protein
[26]. Such levels are high enough to protect mitochondria
against peroxynitrite-mediated damage [27]. The plasma
half-life is about 1h, and the organ half-life is about 60–
135h[22].Thisexplainswhywehaveappliedtheantioxidant
twice daily at intervals of 12 hours. The lack of decrease in
activity of SOD in the group of animals, treated with OVA
+ MnTE-2-PyP is explained by the fact that in vivo they
will be readily reduced by cellular reductants, ﬂavoenzymes,
NO, and so forth, to Mn(II)P [27, 28], which will then in
turn reduce O2
−• to H2O2, acting as superoxide reductases
rather than SOD [29]. Moreover all synthetic SOD mimics
can scavenge peroxynitrite or its degradation products [22].
MnTE-2-PyP is 16-fold more prone to oxidative degradation
than other Mn porphyrins, the commercial, MnTBAP [30].4 The Scientiﬁc World Journal
Table 2: Eﬀect of MnTE-2-PyP on the activity of some enzymes of lung antioxidant defence system in mice asthma model.
28 day after treatment (48 hours after the last inhalation)
Parameters
Groups
Control OVA MnTE-2-PyP OVA + MnTE-2-PyP
SOD activity in U/g 31.1 ±1.79 22.1 ±1.94∗ 28.6 ±1.01 28.6 ±1.25†
mean ± SEM
CAT activity in mcat/g 38.14 29.48∗ 35.91 34.81†
Median (min–max) (33.08–44.12) (21.51–31.20) 31.92–38.72 31.69–43.51
Q3–Q1 5.07 4.30 4.5 9.14
GP activity in U/g 111.2 76.07∗ 115.3 101.5
Median (min–max) 51.4–138.74 66.85–83.56 100.7–118.25 62.27–136.92
Q3–Q1 29.65 6.38 12.74 49.81
NPSH groups in mol/g10−7 0.58 ±0.03 0.40 ±0.03∗ 0.54 ±0.084 0.55 ±0.04†
mean ± SEM
OVA: ovalbumin; MnTE-2-PyP: Manganese (III) 5,10,15,20-tetrakis (N-ethylpyridinium-2-yl) porphyrin; SOD: superoxide dismutase; CAT: catalase; GP:
glutathion peroxidase; NPSH groups: non protein sulfhydryl groups; SEM, standard error of mean; Q3–Q1: interquartile range
∗Diﬀerent from control at P < 0.05;






































































Figure 4: Content of nonprotein sulfhydryl groups in lung
homogenate. Each point represents the mean ± SEM for six mice.
The eﬀects, observed after Mn porphyrins use, were the
consequence not only of mere scavenging of ROS/RNS
(reactive nitrogen species), but also of Mn porphyrins
being able to modulate ROS/RNS-based signaling pathways.
Mn(III) N-alkylpyridylporphyrins inhibit in vitro and in
vivo activation of several redox-controlled transcription
f a c t o r ss u c ha sH I F - 1 α (hypoxia inducible factor 1α), NF-
kB (nuclear factor kappa-B), AP-1 (activating protein-1),
and SP-1 (speciﬁcity protein-1) [31, 32]. MnTE-2-PyP, a
potent SOD mimic/ONOO− scavenger, can strongly inhibit
excessiveactivationofredox-sensitivecellulartranscriptional
activity, particularly suppressing hypoxia inducible factor
1α (HIF-1α)a c t i v a t i o n[ 33]. This results in lowering the
number of inﬂammatory cells and cytokines, which in turn
could lower to the levels of secondary ROS/RNS [34].
Manganese meso-porphyrins have been used successfully
to treat oxidative stress in the numerous disorders such
as stroke [35], spinal cord injury [36], Parkinson disease
[37], Alzheimer disease [38], diabetes [39], cancer [40,
41], ischemia/reperfusion conditions [42, 43], bronchopul-
monary dysplasia [44], asthma [45, 46], lung ﬁbrosis [47],
lung radioprotection [48], and sepsis [49]. The recent study
on the eﬀects of antioxidants, especially mitochondria-
targeted antioxidants, indicated that these compounds may
potentially improve the treatment of widespread and socially
signiﬁcant diseases, such as asthma.
5. Conclusion
The intraperitoneal application of 5mg MnTE-2-PyP, a
manganese meso-porphyrin, twice daily one hour before
nebulization with ovalbumin on days 24, 25, and 26
mitigated the eﬀects of the oxidative stress in asthma mice
model assessed by key antioxidant enzymes and content
of nonprotein sulfhydryl groups in the lungs. MnTE-2-PyP
restored the basic antioxidant enzymes, such as superoxide
dismutase, glutathione peroxidase as well as the content of
the nonprotein sulfhydryl groups in the lungs.
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